Candel Therapeutics (CADL) Interest Coverage Ratio (2020 - 2025)
Candel Therapeutics (CADL) posted Interest Coverage Ratio of 27.3 for Q4 2025, down 2255.43% sequentially from 1.16 in Q3 2025, and down 110.59% YoY from 257.74 in Q4 2024.
Candel Therapeutics (CADL) Interest Coverage Ratio (2020 - 2025) Analysis & Trends
Candel Therapeutics has reported Interest Coverage Ratio for 6 years, with the latest figure at 27.3 in Q4 2025.
- Quarterly Interest Coverage Ratio fell 110.59% year-over-year to 27.3 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was 23.24 (down 51.04% YoY) and the FY2025 annual result came in at 0.74, up 38.84% from the prior year.
- Interest Coverage Ratio fell to 27.3 in Q4 2025 per CADL's latest filing, from 1.16 in the prior quarter.
- Over five years, Interest Coverage Ratio peaked at 0.31 in Q1 2022 and troughed at 45.65 in Q4 2023.
- A 5-year average of 10.94 and a median of 12.23 in 2024 frame the typical range for Interest Coverage Ratio.
- The sharpest annual moves came in 2023 and 2024: Interest Coverage Ratio plunged 5033.99% in 2023, then jumped 96.74% in 2024.
- Over 5 years, Interest Coverage Ratio stood at 0.42 in 2021, then slumped by 3771.11% to 16.2 in 2022, then plunged by 181.79% to 45.65 in 2023, then soared by 71.61% to 12.96 in 2024, then plunged by 110.59% to 27.3 in 2025.
- According to Business Quant data, Interest Coverage Ratio over the past three periods registered 27.3, 1.16, and 0.99 for Q4 2025, Q3 2025, and Q2 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Cover (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 2.84 |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 24.64 |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -0.19 |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 8.18 |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -0.01 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 0.61 |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 2.82 |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -0.08 |
| 10 | Candel Therapeutics | 643.41 Mn | 643.41 Mn | - | -27.30 |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -27.30 |
| Sep 30, 2025 | -1.16 |
| Jun 30, 2025 | -0.99 |
| Mar 31, 2025 | -0.59 |
| Dec 31, 2024 | -12.96 |
| Sep 30, 2024 | -0.43 |
| Jun 30, 2024 | -0.49 |
| Mar 31, 2024 | -12.23 |
| Dec 31, 2023 | -45.65 |
| Sep 30, 2023 | -13.25 |
| Jun 30, 2023 | -0.96 |
| Mar 31, 2023 | -15.82 |
| Dec 31, 2022 | -16.20 |
| Sep 30, 2022 | -17.11 |
| Jun 30, 2022 | -20.12 |
| Mar 31, 2022 | -0.31 |
| Dec 31, 2021 | -0.42 |
| Dec 31, 2020 | -0.54 |